New hope against stomach bug in Antibiotic-Resistant region
NCT ID NCT06382493
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two treatments for H. pylori infection, a common stomach bug. One uses a newer drug called tegoprazan, while the other uses a standard proton pump inhibitor. The trial will enroll 400 adults in South Korea, where antibiotic resistance makes treatment difficult. The goal is to see which approach clears the infection more effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tegoprazan
- What this could lead to
- If successful, this could offer a more effective treatment option for H. pylori infection in regions with high antibiotic resistance.
- What could go wrong
- This is a single-center trial with 400 participants, so results may not apply broadly. The study is early and does not yet prove long-term benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, Gyeonggi-do, 463-707, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a closer look at the stomach spot hidden infections?
- Which antibiotic combo wins against h. pylori? a Head-to-Head test
- Can customizing antibiotics beat stomach bug resistance?
- A supplement may tame the Gut-Wrenching side effects of h. pylori therapy
- Could a fecal transplant beat a stubborn stomach bug?
- AI eye on stomach cancer: 6,000-Person trial tests smarter scopes